Sun 12/16/2018 01:34 ET
DJIA24100.51486.832.02%TELCO165.080.660.40%GOLD1242.305.090.41%Shanghai2593.7439.681.53%
S&P 5002599.9549.661.91%BANKS395.493.760.95%OIL51.231.352.64%BITCOIN3266.0530.700.94%
NASDAQ6910.67156.182.26%PHARM563.0727.874.95%US/EU1.130.000.01%Futures2596.7548.821.88%
Welcome Stranger!  Please sign up or log in to enable additional features.Sign Up | Mail | Log In
Forum - Nabriva Therapeutics AG - NBRV   

Msg Top | Msg List | < Prev | Next > | Post New | Reply | Privately | Search | Add NBRV
  
From: burp (Rep: 64) reply to singhtelecomDate: 04/13/2018 07:13
Forum: Nabriva Therapeutics AG - Msg #43Thread #674002245 (Rec: 0)
DUBLIN, Ireland, April 13, 2018 (GLOBE NEWSWIRE) -- Nabriva Therapeutics Plc (NASDAQ:NBRV), a clinical stage biopharmaceutical company engaged in the research and development of novel anti-infective agents to treat serious infections, with a focus on the pleuromutilin class of antibiotics, today announced that it will present data at the 28th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) taking place in Madrid, Spain from April 21-24, 2018.

These data are part of a growing body of evidence supporting lefamulin's profile as a promising first-in-class pleuromutilin antibiotic treatment for key pathogens, including multidrug resistant strains, known to cause community-acquired bacterial pneumonia (CABP).

“CABP is associated with a substantial economic and humanistic burden with significant morbidity and mortality for patients. With inappropriate use of currently available treatments, antibacterial resistance continues to rise. It is imperative that new classes of antibiotics continue to be developed to provide physicians treatment options for patients with serious infections,” said Jennifer Schranz, M.D., chief medical officer of Nabriva Therapeutics. “Following the positive results from LEAP 1, lefamulin has shown to provide a complete spectrum of activity that covers the most common bacterial causes of CABP, including multidrug resistant strains and atypical pathogens. We look forward to reporting topline efficacy and safety data from our LEAP 2 oral CABP trial this spring.”Re: I have few calls MAY strike 5 at 1.00 Re: She's going! Re: $4.90 HOD...Re: $...



Reply to singhtelecom - Msg #2729413 - 04/12/2018 22:51

I have few calls MAY strike 5 at 1.00 Re: She's going! Re: $4.90 HOD...Re: $167M M/C is a joke..Last $4.45 Buyout comi...
What would you like to do? Message: Endorse | Bookmark | Report AbuseUser burp: Reward | Watch | IgnoreNBRV: Ignore

Msg Top | Msg List | < Prev | Next > | Post New | Reply | Privately | Search | Add NBRV
  

TheLion.com | About Us | Agreement & Disclaimer | Privacy | Twitter
© 1999- TheLion.com, Inc.